【摘 要】
:
Background.Anaemia in haemodialysis patients can be effectively treated with erythropoietin.We investigated whether subcutaneous (SC) epoetin β administered once weekly was as effective as the same we
【机 构】
:
Department of Nephrology, Centralsjukhuset, Karlstad
【出 处】
:
2013年中国肾性贫血治疗专家共识研讨会
论文部分内容阅读
Background.Anaemia in haemodialysis patients can be effectively treated with erythropoietin.We investigated whether subcutaneous (SC) epoetin β administered once weekly was as effective as the same weekly dosage given in two to three divided doses.Methods.One hundred and fifty-eight patients (delivered Kt/V > 1.0, where K=dialyser-renal urea clearance, t=dialysis time and V=filtration volume,obtained by urea kinetic modelling) were randomized to treatment with SC epoetin β either once weekly (n=118), or to their original dosage two or three times weekly (control group, n=40) for 24 weeks.All patients received intravenous iron supplementation when necessary.Results.Eight-eight patients in the once weekly group and 30 patients in the control group were treated for at least 16 weeks and are included in the analysis.Stable haemoglobin levels were maintained without epoetin dose increases in 73% of patients in both groups.Mean haemoglobin levels at randomization and after 16 and 24 weeks were 11.4, 11.1 and 11.1 g/dl,respectively, in the once weekly group compared with 11.2, 11.3 and 11.2g/dl, respectively, in the control group.The mean weekly epoetinβ dosages at randomization and after 16 and 24 weeks were 102, 103 and 106 IU/kg bodyweight, respectively, in the once weekly group compared with 109, 109 and 115 IU/kg bodyweight, respectively, in the control group.No statistically significant between-group differences were apparent for changes in haemoglobin levels or epoetin β dosages at week 24.Conclusions.Once weekly SC administration of epoetin β is as safe and effective in maintaining haemoglobin levels in stable haemodialysis patients as two or three times weekly administration of the same total dose.By using the once weekly regimen, patients can avoid up to 104 injections per year.This would reduce clinic time for patients who do not self administer, and may also encourage self-administration and improve overall compliance.
其他文献
Background: Previous analyses report the impact of erythropoiesis-stimulating agents (ESAs) on health-related quality of life across various populations.In this analysis, we review published studies a
Background: The role of erythropoiesis-stimulating agents (ESAs) in treating the anemia of chronic kidney disease has been reevaluated in view of recent studies suggesting that the use of these agents
BACKGROUND Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established.METHODS We randomly assigned 603 patients with an estim
AlthOugh treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most studies have examined associations between baseline hemoglobin values and survi
It is unclear whether physiologic hemoglobin targets lead to cardiac benefit in incident hemodialysis patients without symptomatic heart disease and left ventricular dilation.In this randomized, doubl
Background and objectives: The effects of different hemoglobin targets when using erythropoiesis-stimulating agents on quality of life are somewhat controversial, and predictors of change in quality o
Treatment for anemia has come a long way in the last 20 years since the first recombinant human erythropoietins were licensed for the management of anemia in chronic kidney disease.The first-generatio
Epoetin alfa and beta are the two forms of recombinant DNA-derived erythropoietin (rEPO), both synthesized in Chinese hamster ovary cells, which are used for the treatment of erythropoietin (EPO)-resp
In May 2009 for financial reasons, the epoetin product used for hemoglobin (Hb) maintenance in our renal dialysis unit was changed from epoetin beta to epoetin alfa.Although widely believed that the d
Patients may complain of pain at the injection site after subcutaneous (s.c.) administration of erythropoietin (EPO).Local pain due to s.c.EPO into the thigh was evaluated in 60 hemodialysis patients